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SMR FOR CANCER MORTALITY IN UMHAUSEN (WESTERN
TYROL, AUSTRIA) FOR 1970-91
*p < 0 05. Obs = observed, exp = expected
medians on the ground floors amounted to 1180 Bq/m3 (maximum
88 000 Bq/m3) in winter and 210 Bq/m3 (maximum 52 000 Bq/m3)
in summer, compared with an average of 20 Bq/m3 in the UK.4 In
basements, the respective medians were higher by a factor of 2-3
than on the ground floor. The maximum amount measured was
274 000 Bq/m3.
Mortality data for 1970-91 were used to calculate age and sex
standardised mortality rates (SMR) for 51 sites of carcinoma. The
total population of Tyrol were controls. A significantly higher risk
was recorded for lung cancer (table). The high SMR for lung cancer
in female subjects is especially striking. Because case numbers were
low for the other cancer sites, these were combined in one group to
calculate the SMR. No significant increase in SMR was found for
this group. The coincidence of unusually high indoor radon
concentrations with high SMR for lung cancer, although highly
conspicuous, is not proof of a causal relation. An analysis of
confounding factors is in progress. Although scientific proof of an
association between unusually high indoor radon concentrations
and lung cancer is still outstanding, remedial measures have been
initiated.
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ACE inhibitors for myocardial infarction and
unstable angina
SIR,-We appreciate the considerable interest in our report (Nov
14, p 1173). In particular, we would clarify the issues raised by Dr
Hall and colleagues (Dec 19/26, p 1547). They note an apparent
discrepancy between the numbers of patients classified as having a
fatal myocardial infarction (MI) in our two reports on mortality
from the treatment trial’ and prevention trial2 compared with the
detailed report on ischaemic events. In these reports, a fatal MI was
identified when the principal investigator at each clinic or a death
certificate identified the cause of death as having been due to MI. In
analysing the data for the latter report we noted that in a few
instances, a patient may have had an MI and died within a few days
but the cause of death was identified as being due to pump failure or
arrhythmias. To have a consistent separation between fatal and
non-fatal MI, we arbitrarily separated all deaths within 7 days for an
MI as fatal and the remainder as non-fatal events. Irrespective of
these distinctions between fatal and non-fatal MI, the total number
of MI in each of the two randomised groups is unchanged.
Moreover, the difference between enalapril and placebo groups in
the number of fatal MI by either definition is almost identical
(difference in combined trials based on the New England Journal of
Medicine articles is 19, and on the Lancet article, difference is 18),
indicating the robustness of our results.
The numbers of deaths during the placebo run-in phase, which
averaged 15 days, was 34 in 7092 patients (0-22% per week),
compared with 4 deaths during the active run-in phase, which
averaged 6 days in 7402 patients (0-06% per week). These data
provide no evidence of early harm by the use of enalapril.
The issues raised by Dr Chaudhary and colleagues and by Dr
Cruickshank (Dec 19/26, p 1547) warrant further studies of the
effect of angiotensin-converting enzyme inhibitors in other high
risk populations without low ejection fraction and heart failure.
These studies should be ideally complemented by detailed
mechanistic studies (eg, angiographic or ultrasound assessments of
atherosclerosis) so that the generalisability of intriguing findings of
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Phosphocreatine turnover and pH balance in
forearm muscle of patients with syndrome X
SIR,-Syndrome X might encompass several pathophysiological
entities.1 However, data on obvious restriction of flow is lacking and
because perfusion disorders of skeletal muscle are unlikely, we
speculate that an inherent metabolic defect could explain the low
energy charge. Our first results derived from muscle biopsy
specimens.2 To get in-vivo data, we investigated skeletal muscle
oxidative performance by 3’P nuclear magnetic resonance (NMR)
spectroscopy of the forearm at rest and during exercise and recovery
from exercise. In-vivo 31P-NMR spectroscopy allows following the
changes in phosphorus metabolite levels and intracellular pH in
human skeletal muscle non-invaseively.3 3
We investigated 2 patients with syndrome X in a series of 7 in
which myocardial and skeletal muscle biopsy samples showed low
energy charged The patients were chosen according to clinical
presentation, 1 having heavy symptoms with angina and the other
being clinically less severe. 8 informed, healthy/untrained, male
volunteers aged 24-51 years acted as controls. NMR spectroscopy
was done on a Bruker Biospec 24/30 with a 2-35 T magnet, giving an
operating frequency of 40-55 MHz for 31 P nuclei. The 31P-NMR
spectra from the forearm muscles were acquired by accumulating
128 FIDs with a repetition rate of 1 s and a radio frequency pulse
length of 125 ill (70&deg; flip angle). During exercise and recovery,
spectra were collected continuously after the completion of 4 scans.
The phosphocreatine (PCr), inorganic phosphate (Pi),
phosphomonoesters (PME), and the fx, &bgr;, y-ATP resonances were
identified from their chemical shifts and calculated.’ Spectra from
the patients were obtained at rest, during 12 min of exercise, and
during 12 min of recovery. Exercise involved handgrip training
equipment equilibrated to 100 N and each subject worked at 20% of
his own maximum capacity. Myocardial biopsy specimens from the
2 patients displayed low energy charge values (0-56 and 0-59,
respectively). Also, energy charge of skeletal muscle biopsy samples
were abnormal (0-56 and 0-69, respectively).
Changes in PCr were followed continuously, spectroscopically,
and expressed as PCr/(PCr + Pi). The initial resting values of the 2
patients and the controls for PCr and intracellular pH were similar.
During exercise the rate of decrease of PCr and of pH was greater in
patients than in controls (figure). PCr fell to 42% and 48% in the
less severe patient, and to 58% (mean) of initial resting values in
controls after 12 min of exercise. PCr resynthesis during post-
exercise recovery was faster in controls. After exercise, pH was
significantly lower in the patients (596 and 6-68, respectively) than
